-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FpBXDGdxB3teSQfsVYJ5JprZo82AUYGY3Av1eoHNp4oDqNpSuYrizk+fLWfJFnAk C+Sbz+yKDd1Ejg2elfrfjQ== 0001181431-08-037033.txt : 20080605 0001181431-08-037033.hdr.sgml : 20080605 20080605145339 ACCESSION NUMBER: 0001181431-08-037033 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080530 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080605 DATE AS OF CHANGE: 20080605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ CENTRAL INDEX KEY: 0000918112 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943049219 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23280 FILM NUMBER: 08882797 BUSINESS ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 800 CITY: EMERYVILLE STATE: CA ZIP: 94608 BUSINESS PHONE: 510-595-6000 MAIL ADDRESS: STREET 1: 2000 POWELL STREET, SUITE 800 CITY: EMERYVILLE STATE: CA ZIP: 94608 8-K 1 rrd209958.htm Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  05/30/2008
 
NEUROBIOLOGICAL TECHNOLOGIES INC /CA/
(Exact name of registrant as specified in its charter)
 
Commission File Number:  000-23280
 
Delaware
  
943049219
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
2000 Powell Street, Suite 800,
Emeryville, California 94608
(Address of principal executive offices, including zip code)
 
(510) 262-1730
(Registrant’s telephone number, including area code)
 
NOT APPLICABLE
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
 
On May 30, 2008, at the Special Meeting of Stockholders of Neurobiological Technologies, Inc. (the "Company"), the Company's stockholders approved a proposal to amend the Company's Amended and Restated 2003 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance thereunder by 3,200,000 shares, to increase the size of the annual non-employee director grant to 15,000 shares and to make certain other changes as described in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 3, 2008 and amended on May 23, 2008 (collectively, the "Proxy Statement").   The amendments became effective upon stockholder approval.   A summary of the material terms of the Plan can be found in the Proxy Statement, and such summary is incorporated by reference herein.
 
 
Item 9.01.    Financial Statements and Exhibits
 
Amended and Restated 2003 Equity Incentive Plan of Neurobiological Technologies, Inc., as amended and restated effective May 30, 2008 (incorporated by reference to Appendix A to the Company's Definitive Proxy Statement on Schedule 14A filed with the SEC on April 3, 2008).
 

 

Signature(s)
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
      
 
NEUROBIOLOGICAL TECHNOLOGIES INC /CA/
 
 
Date: June 05, 2008
     
By:
 
/s/    Matthew M. Loar
               
Matthew M. Loar
               
Vice President and Chief Financial Officer
 
 
 -----END PRIVACY-ENHANCED MESSAGE-----